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doi:10.1016/j.jtcvs.2004.03.039Nomori and colleagues1 demonstrate the relationship between con-trast ratio derived from F-18 fluorodeoxyglucose positron emis-sion tomography (FDG-PET) in cT1 N0 M0 lung adenocarcinomaand pathologic TNM classification, carcinoembryonic antigenlevels, lymphatic and vascular invasion, pleural involvement, andtumor differentiation. These observations constitute the scientific
merit of the study. Quite properly, the authors go on to ask what the findings mean
and, in particular, what clinical inferences they suggest. Based on what appears to
be 100% sensitivity of the imaging test, they conclude that if the contrast ratio is less
than 0.5, “limited lung resection could be indicated, lymph node dissection or
mediastinoscopy could be reduced, or both.”
At the heart of these seemingly logically derived clinical inferences lies treach-
ery. We must be quick to state that these same or similar inferences would be drawn
by more than 90% of the readership, not just in this context but also in the general
context of interpreting the accuracy of any diagnostic test; the authors are well
within the mainstream. It is the rare reader who knows that the lid has been blown
off many diagnostic tests, particularly the ones cardiologists and cardiac surgeons
have come to rely on in ischemic heart disease. Heretofore, our training and
backgrounds have been deficient in interpreting the accuracy of diagnostic testing.
We have been misled by our ignorance. The data have not been false, but the
interpretation and inferences have been.
What Went Wrong
Nomori and colleagues1 provide important details that give us not only insight into
the value of their study but also a clue about the trap they have innocently set for
the unsuspecting. The 44 patients presented are a highly selected subset of patients
who had (1) major lung resection with mediastinal lymph node dissection and
pathologic classification of disease (gold standard or reference standard), (2)
tumors of specified size (large enough to be resolved by FDG-PET scanning) and
characteristics (3 cm, noncalcified nodule), and (3) a specific clinical diagnosis of
cancer stage based at least in part on the very test they evaluated. Figure 1 shows
a patient flow diagram formatted as suggested by the recently published Standards
for Reporting of Diagnostic Accuracy (STARD) Initiative.2 Note the many question
marks accompanying various n values. What is apparent is that the 44 cases belong
to a large group of noncalcified malignant tumors less than 3 cm in diameter on
computed tomography, and that these were themselves a subset of 223 patients,
probably most of whom did not have a gold standard (reference) diagnosis. A
diagram like this shows the many ways bias can be introduced and lead to
unjustified inferences.
Narrowing down a study to a defined patient subset is necessary to examine the
relationship of diagnostic test results to particular kinds of pathology, as in Nomori
and colleagues’ article.1 But it makes extrapolation of test results to the more
general population (including our very next patient), whose pathology is not yet
known, treacherous. Specifically, it is now known that if a test has been used to
select patients—that is, has been used for its intended diagnostic purpose—and it is
predominantly only patients with positive test results for whom gold standard
verification of disease is obtained, then for that group of patients, sensitivity of the
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Ltest is artificially inflated, often by vast amounts, and spec-
ificity is simultaneously deflated.3 Thus, the unsuspecting
reader may conclude that a contrast ratio of less than 0.5 on
FDG-PET scanning is 100% sensitive and therefore useful
for making the kind of surgical decisions suggested (spe-
cifically, not needing to perform a gold standard operation).
In fact, it would be surprising if the test were more than 40%
to 60% sensitive if it follows the pattern unfolding for
diagnostic testing that affects cardiac surgery decisions!
The particular problem here, and the only one we dwell
Figure 1. Partial reconstruction of patient flow diagram
recommended in the STARD Initiative.2,25 Many details
not be reconstructed from data supplied in the manuson in this editorial, is known as work-up bias.
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Ransohoff and Feinstein4 coined the term work-up bias for
their 1978 New England Journal of Medicine expose´ of bias
in diagnostic testing. Work-up bias occurs whenever a test
is performed and a gold standard (reference) validation is
not performed for each patient, and accuracy of the test is
reported for only patients with reference validation. This is
particularly apt to occur when the gold standard involves an
invasive procedure, such as obtaining pathologic tissue in
lung cancer. It also occurs when patients with a positive
2
study group of Nomori and colleagues in the fashion
oxes are missing from the diagram because they could
.for
and bresult go on to further testing (sequential-ordering bias ).
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LWork-up bias, or slight variants of it, has been called
verification bias,5,6 validation bias,7 referral bias,8,9 sam-
pling bias,10 and selection bias.10-13
The effect of work-up bias on purported accuracy of a
diagnostic test is illustrated in Figure 2.14 Patients with a
positive test result are likely to undergo a procedure for
tissue pathologic verification, resulting in a disproportion-
ately large share of patients undergoing verification having
a positive test. Sensitivity (positive test when disease is
present) appears to be high. As a corollary, because few
patients undergoing an invasive procedure will have had a
negative test result, few of the patients found not to have
pathologic disease will have had a negative test. Thus,
specificity will appear poor (negative pathology in patients
with negative test results).
What is important for readers to grasp is the magnitude
of work-up bias on what we have been led to believe is the
accuracy of the test. Take prostate-specific antigen (PSA)
screening for prostate cancer, for which work-up bias is
introduced from selective biopsy (gold standard). It has
been suggested that the threshold for biopsy, a PSA level of
4.1 ng · mL1 or greater, should be lowered to improve test
sensitivity.15 For men under the age of 60 years, it is thought
that sensitivity of PSA screening is 57%, with 60% speci-
ficity. Punglia and colleagues15 found that after adjustment
for work-up bias, sensitivity was only 18%; that is, 82% of
cancers are missed! However, specificity was 98%; that is,
only 2% of men without cancer have a positive test result.
In diagnosis of ischemic heart disease, simple stress testing
is thought to have a sensitivity of 67% and a specificity of
73%.16 In a Veterans Affairs study, in which patients re-
ferred for stress testing were required to undergo gold
standard cardiac catheterization (eliminating work-up bias),
the test was found to have a true sensitivity of only 44% but
a reasonable specificity of 87%. Thus, better tests—imaging
tests—were developed, such as stress echocardiography.
This test was once thought to have 80% sensitivity for
coronary artery disease and 45% specificity, but after ac-
counting for work-up bias, these were about 40% and 85%,
respectively!17 In the early days of exercise radionuclide
testing, Rozanski and colleagues18 found over a 5-year
period that specificity of the test decreased from 84% to
27% as the spectrum of cases (spectrum bias) narrowed and
its use as a screening test for angiography increased
(work-up bias). Just the inverse (low to high) happened to
sensitivity.
Why Are We Misled?
Of all diagnostic testing biases, work-up bias is the most
counterintuitive.19 Logically, a test’s reference values, such
as sensitivity and specificity, should be computed by using
the subgroup of patients for whom a gold standard test has
been made. However, we fail to appreciate that the results of
The Journal of Thoracithe diagnostic test have themselves determined which pa-
tients will receive a gold standard test and which will not.
Thus, we have observed lack of work-up bias only in
settings in which a surgeon does not believe in the test or
ignores it for purposes of decision making, always gets the
test results “after the fact,” or follows a protocol that re-
quires gold standard testing no matter what is found in
diagnostic testing. Otherwise, there is a strong correlation
between the test results and performance of gold standard
testing,20-24 hence bias.
What to Do
Faith in diagnostic tests is being shattered just as “shopping
mall diagnostics” are taking off! Although shoppers who
submit to such testing are probably a somewhat biased
group, they are more likely than known ill patients to
represent the general population. Therefore, without
work-up bias, one will find these tests rather insensitive in
picking up existing disease, but considerably more specific
(fewer false-negative results) than we are accustomed to
thinking.
So alarming is the present state of diagnostic testing
reporting that journals are adopting the STARD check-
list.2,25 The STARD Initiative was an international effort
stimulated by growing recognition of biases that have
fooled us all. Group members developed a 25-item checklist
with cryptic explanation. Work-up bias is included in item
16: “The number of participants satisfying the criteria for
inclusion that did or did not undergo the index test and/or
the reference standard; describe why participants failed to
receive either test (a flow diagram is strongly recom-
mended).” This deceptively simple statement hardly seems
to address biases, but it is absolutely fundamental because it
is the nature of the patients tested and the influence of the
Figure 2. Simplified illustration of work-up bias in interpreting
FDG-PET imaging in lung cancer. Few patients with a negative
test result undergo gold standard pathologic verification of the
test. Because patients with positive test results preferentially
undergo invasive pathologic verification, test sensitivity is artifi-
cially inflated.test on whether the diagnosis is verified that introduce bias.
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LWith respect to the article by Nomori and colleagues,1
the STARD statement seems not to preclude publishing
such articles.26 Rather, it encourages authors to state care-
fully all subsets of their population and to consider the many
sources of bias. It is presumed that authors (and readers)
will use that information in interpreting their data, being
particularly careful not to extrapolate conclusions to pa-
tients with yet unknown extent of disease.
Is warning, awareness, or even a 25-point checklist suf-
ficient? We would suggest that as a minimum, such articles
acknowledge that accuracy of testing has not been corrected
for bias. Perhaps in the face of the rampant misinterpretation
of test accuracy, whenever it is possible to estimate magni-
tude of the bias, correction of referent values for bias should
be required.12,13
All Is Not Lost
If the reader’s appropriate profound disillusion with diag-
nostic testing has now reached the level of despair, we
suggest that just because a test performs poorly diagnosti-
cally (once work-up bias is accounted for) does not neces-
sarily mean it is useless clinically. It may be that the test still
has substantial prognostic value. This has been found to be
the case, for example, with stress testing.27 Schro¨der and
Kranse28 suggest that new recommendations for prostate
cancer screening should arise from the European Screening
for Prostate Cancer trial and the Prostate, Lung, Colorectal
and Ovary trial, which focus on whether screening reduces
mortality. That is, they seem to be suggesting that screening
tests should focus on long-term results rather than accuracy
of diagnosis. Screening tests may also be of value for
identifying patients most likely to respond to therapy, par-
ticularly those therapies that carry important morbidity,
such as chemoradiotherapy. Of course, study of prognostic
importance requires long-term clinical studies and well-
designed clinical trials, which are clearly more difficult and
expensive to perform than studies of diagnostic accuracy.
Further Reading
For cardiothoracic surgeons, we highly recommend the ar-
ticle by Kelly and associates,8 who review a large number of
sources of bias in diagnostic imaging for esophageal cancer.
The Mayo Clinic group provides an appendix that illustrates
Begg and Greenes’ method for correcting work-up bias.9
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